AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 785084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (beta‐Acetyldigoxin)
Number of subjects: 46
Study 31771409 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor imaging (DTI)
Number of subjects: 75
Study 31771409 — intervention group
Group type: COMPARATOR
Intervention: T2-weighted imaging
Number of subjects: 75
Study 30790069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegilodecakin monotherapy
Number of subjects: 0
Study 30790069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegilodecakin in combination with anti-PD-1 inhibitors
Number of subjects: 0
Study 30790069 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegilodecakin with FOLFOX
Number of subjects: 0
Study 27878543 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal model
Number of subjects: 332
Study 27878543 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal model
Number of subjects: 332
Study 25731073 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (one-page information sheet about hydrocodone-acetaminophen, given and read aloud)
Number of subjects: 274
Study 25731073 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 274
Study 25731073 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 274
Study 23062389 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal aerosol 320 mg/d
Number of subjects: 340
Study 23062389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study 21349587 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated depressive symptoms (DS)
Number of subjects: 1372
Study 21349587 — intervention group
Group type: COMPARATOR
Intervention: No elevated depressive symptoms (non-depressed women)
Number of subjects: 1372
Study 19156009 — intervention group
Group type: EXPERIMENTAL
Intervention: PureVision multifocal contact lens
Number of subjects: 20
Study 19156009 — intervention group
Group type: COMPARATOR
Intervention: Monovision with PureVision single vision lenses
Number of subjects: 20
Study 19156009 — intervention group
Group type: EXPERIMENTAL
Intervention: High addition multifocal lens
Number of subjects: 20
Study 17365897 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 49
Study 15110882 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg d.i.v. twice daily for 5 days) combined with granisetron (3 mg d.i.v. on the first day) and dexamethasone (16 mg d.i.v. on the first day, 8 mg d.i.v. on days 2, 3, and 4)
Number of subjects: 171
Study 15110882 — intervention group
Group type: COMPARATOR
Intervention: Placebo combined with granisetron (3 mg d.i.v. on the first day) and dexamethasone (16 mg d.i.v. on the first day, 8 mg d.i.v. on days 2, 3, and 4)
Number of subjects: 171
Study 15110882 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg d.i.v. twice daily for 5 days)
Number of subjects: 171
Study 15110882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 11673125 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper sulfate (soluble copper)
Number of subjects: 45
Study 11673125 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper oxide (insoluble copper)
Number of subjects: 45
Study 10164160 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 8239224 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, 400 mg daily
Number of subjects: 126
Study 8239224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 3553336 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-affinity-purified tetanus toxoid vaccine
Number of subjects: 205
Study 3553336 — intervention group
Group type: COMPARATOR
Intervention: Standard (commercial) tetanus toxoid vaccine
Number of subjects: 205
Study 30232110 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse childhood experiences (ACEs)
Number of subjects: 192
Study 30232110 — intervention group
Group type: EXPERIMENTAL
Intervention: Connectedness and social support
Number of subjects: 192
Study 30232110 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual activities
Number of subjects: 192
Study 30232110 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific support
Number of subjects: 192
Study 30232110 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support and diabetes-specific social support
Number of subjects: 192
Study 26691410 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 17
Study 26691410 — intervention group
Group type: COMPARATOR
Intervention: Isovolumic placebo (saccharin-flavored) drink
Number of subjects: 17
Study 24144308 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R (melphalan-prednisone-lenalidomide followed by lenalidomide maintenance)
Number of subjects: 0
Study 24144308 — intervention group
Group type: EXPERIMENTAL
Intervention: MPR-R
Number of subjects: 0
Study 24144308 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan-prednisone)
Number of subjects: 0
Study 22363492 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin administration
Number of subjects: 261
Study 19819634 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg kg(‐1) ketamine
Number of subjects: 24
Study 19819634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) tramadol + 30 min later 1 microg kg(‐1) dexmedetomidine + 2 mg kg(‐1) ketamine
Number of subjects: 24
Study 19819634 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg kg(‐1) tramadol + 30 min later 0.05 mg kg(‐1) midazolam + 2 mg kg(‐1) ketamine
Number of subjects: 24
Study 17485968 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory decision making (PDM) style
Number of subjects: 554
Study 15900306 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio (high in plant sterols, soy protein, viscous fibers, and almonds)
Number of subjects: 34
Study 15900306 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin (20 mg lovastatin)
Number of subjects: 34
Study 15900306 — intervention group
Group type: COMPARATOR
Intervention: Control (very low-saturated fat diet)
Number of subjects: 34
Study 12164888 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume tracking (BVT)
Number of subjects: 36
Study 12164888 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemodialysis
Number of subjects: 36
Study 7698386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-gemeprost
Number of subjects: 153
Study 7698386 — intervention group
Group type: COMPARATOR
Intervention: Rivanol-oxytocin (immediate)
Number of subjects: 153
Study 7698386 — intervention group
Group type: COMPARATOR
Intervention: Rivanol-oxytocin (16-h)
Number of subjects: 153
Study 2527856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone and local anaesthetic injected into two facet joints
Number of subjects: 109
Study 2527856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisone and local anaesthetic injected around two facet joints
Number of subjects: 109
Study 2527856 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline injected into two facet joints
Number of subjects: 109
Study 363629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (two preparations)
Number of subjects: 60
Study 363629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 363629 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician therapists
Number of subjects: 60
Study 363629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonphysician therapists
Number of subjects: 60
Study 31255591 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass drug administration (MDA) with praziquantel alone (arm 1)
Number of subjects: 8278
Study 31255591 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass drug administration (MDA) with snail control (arm 2)
Number of subjects: 8278
Study 31255591 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass drug administration (MDA) with behaviour change activities (arm 3)
Number of subjects: 8278
Study 28865830 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacilli
Number of subjects: 0
Study 28865830 — intervention group
Group type: COMPARATOR
Intervention: Standard milk
Number of subjects: 0
Study 24938711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B group (800 µg/day of folate, 10 mg of vitamin B6, 25 µg of vitamin B12)
Number of subjects: 104
Study 24938711 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 104
Study 24938711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B group
Number of subjects: 104
Study 23593636 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% citric acid + 2% CHX with rotary instrumentation
Number of subjects: 48
Study 23593636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl + 17% EDTA with rotary instrumentation
Number of subjects: 48
Study 23593636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl + 17% EDTA with RealSeal
Number of subjects: 48
Study 23593636 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl + 17% EDTA with EndoREZ
Number of subjects: 48
Study 21768610 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to aripiprazole
Number of subjects: 215
Study 21768610 — intervention group
Group type: COMPARATOR
Intervention: Stay on current medication (olanzapine, quetiapine, or risperidone)
Number of subjects: 215
Study 21768610 — intervention group
Group type: COMPARATOR
Intervention: Stay on current medication
Number of subjects: 215
Study 18937957 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 406
Study 18937957 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplementation
Number of subjects: 406
Study 18937957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 17076978 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 94
Study 17076978 — intervention group
Group type: COMPARATOR
Intervention: Travoprost 0.004%
Number of subjects: 94
Study 15566075 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiogram (MCG)
Number of subjects: 86
Study 15566075 — intervention group
Group type: COMPARATOR
Intervention: 12-lead ECG
Number of subjects: 86
Study 11779098 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (750 U/kg a week) administered for 6 weeks starting on the 10th day of life
Number of subjects: 40
Study 11779098 — intervention group
Group type: COMPARATOR
Intervention: Control group (no r‐HuEPO treatment)
Number of subjects: 40
Study 9929207 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated coding
Number of subjects: 38
Study 9929207 — intervention group
Group type: COMPARATOR
Intervention: Manual coding
Number of subjects: 38
Study 7995329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam with Diazoxide
Number of subjects: 10
Study 7995329 — intervention group
Group type: COMPARATOR
Intervention: Diazoxide
Number of subjects: 10
Study 7995329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam
Number of subjects: 10
Study 2661768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine plus azathioprine plus prednisolone (group A)
Number of subjects: 60
Study 2661768 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine and azathioprine alone (group B)
Number of subjects: 60
Study 2661768 — intervention group
Group type: COMPARATOR
Intervention: Maintenance steroids (group C)
Number of subjects: 60
Study 29865884 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-control resources depleted
Number of subjects: 32
Study 29865884 — intervention group
Group type: COMPARATOR
Intervention: Self-control resources not depleted
Number of subjects: 32
Study 30188953 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting muscarinic antagonists (SAMAs)
Number of subjects: 12774
Study 30188953 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta-agonists (SABAs)
Number of subjects: 12774
Study 30188953 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin
Number of subjects: 12774
Study 30188953 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 12774
Study 30188953 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD cohort
Number of subjects: 12774
Study 30188953 — intervention group
Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 12774
Study 29145792 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (two sessions delivered at home by local community health workers)
Number of subjects: 0
Study 29145792 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 25970665 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 13
Study 25970665 — intervention group
Group type: COMPARATOR
Intervention: Gluten-containing diet (GCD)
Number of subjects: 13
Study 23890536 — intervention group
Group type: EXPERIMENTAL
Intervention: Video self-instruction (VSI) on CPR and AEDs
Number of subjects: 1616
Study 21748765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times a day
Number of subjects: 55
Study 21748765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19916995 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg)
Number of subjects: 16
Study 19916995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16534710 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational Therapy (OT)
Number of subjects: 100
Study 16534710 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - Conventional care
Number of subjects: 100
Study 12766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine and fentanyl before incision (group 1)
Number of subjects: 141
Study 12766657 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural saline before incision and epidural lidocaine and fentanyl 40 min after incision (group 2)
Number of subjects: 141
Study 12766657 — intervention group
Group type: COMPARATOR
Intervention: Sham epidural control (group 3)
Number of subjects: 141
Study 10966142 — intervention group
Group type: EXPERIMENTAL
Intervention: Short opponens splint
Number of subjects: 26
Study 10966142 — intervention group
Group type: EXPERIMENTAL
Intervention: Long opponens splint
Number of subjects: 26
Study 9314127 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg i.v., n = 60)
Number of subjects: 80
Study 9314127 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.15 mg/kg i.v.)
Number of subjects: 80
Study 9314127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 80
Study 7880947 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 44
Study 7880947 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 44
Study 7880947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium administration with i.v. induction and pre-treatment with alcuronium 0.04 mg kg‐1
Number of subjects: 40
Study 3378554 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium administration with i.v. induction without pre-treatment
Number of subjects: 40
Study 3378554 — intervention group
Group type: EXPERIMENTAL
Intervention: Suxamethonium administration with inhalation induction and pre-treatment with alcuronium 0.04 mg kg‐1
Number of subjects: 40
Study 3378554 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium administration with inhalation induction without pre-treatment
Number of subjects: 40
Study 29582734 — intervention group
Group type: EXPERIMENTAL
Intervention: Norovirus vaccine interest survey
Number of subjects: 627
Study 29582734 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education households
Number of subjects: 627
Study 29582734 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower WTP households
Number of subjects: 627
Study 27538743 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucobrassicin doses ranging from 25 to 500 μmol, once daily for 2 consecutive days
Number of subjects: 45
Study 25614139 — intervention group
Group type: EXPERIMENTAL
Intervention: Families Improving Together (FIT) intervention
Number of subjects: 0
Study 22971593 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid testing with information only
Number of subjects: 12
Study 22971593 — intervention group
Group type: EXPERIMENTAL
Intervention: On-site rapid testing with risk-reduction counseling
Number of subjects: 12
Study 22971593 — intervention group
Group type: COMPARATOR
Intervention: Off-site testing referral
Number of subjects: 12
Study 20876596 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ml of sucrose 24% given by mouth using a syringe and a soother
Number of subjects: 40
Study 20876596 — intervention group
Group type: COMPARATOR
Intervention: 0.2 ml of sterile water given by mouth using a syringe and a soother (Control)
Number of subjects: 40
Study 18376000 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 720
Study 18376000 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus Ezetimibe (10 mg)
Number of subjects: 720
Study 16772456 — intervention group
Group type: EXPERIMENTAL
Intervention: High dry bean intake (highest quartile of change in intake)
Number of subjects: 0
Study 16772456 — intervention group
Group type: COMPARATOR
Intervention: Control group (lowest quartile of dry bean intake)
Number of subjects: 0
Study 12691335 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS40 (40 minutes)
Number of subjects: 38
Study 12691335 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS60 (60 minutes)
Number of subjects: 38
Study 12691335 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS20 (20 minutes)
Number of subjects: 38
Study 12691335 — intervention group
Group type: COMPARATOR
Intervention: TENS(PL) (60 minutes placebo)
Number of subjects: 38
Study 11053614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (2 g daily)
Number of subjects: 18
Study 11053614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9120226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy (9.7 through 19.1 mg/kg/day)
Number of subjects: 33
Study 9120226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 9120226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin monotherapy
Number of subjects: 33
Study 1552457 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-01 (controlled-release insert containing ofloxacin) applied once a week for 4 weeks
Number of subjects: 46
Study 1552457 — intervention group
Group type: COMPARATOR
Intervention: Control insert without any antibacterial agent
Number of subjects: 46
Study 3537822 — intervention group
Group type: EXPERIMENTAL
Intervention: Chymodiactin
Number of subjects: 1606
Study 3537822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1606
Study 28927866 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive training for BPD
Number of subjects: 74
Study 28927866 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation training
Number of subjects: 74
Study 27113598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronome cueing
Number of subjects: 12
Study 27113598 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashing light cueing
Number of subjects: 12
Study 27113598 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic flow cueing
Number of subjects: 12
Study 27113598 — intervention group
Group type: COMPARATOR
Intervention: No-cue (control condition)
Number of subjects: 12
Study 24690207 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue (Tisseel)
Number of subjects: 82
Study 24690207 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 82
Study 24447354 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular heparin 4 kU once a day for 7 days
Number of subjects: 63
Study 24447354 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 63
Study 20643390 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring
Number of subjects: 0
Study 20643390 — intervention group
Group type: COMPARATOR
Intervention: Low-dose oral contraceptive (OC)
Number of subjects: 0
Study 18761479 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 53
Study 18761479 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual learning
Number of subjects: 53
Study 15919453 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI withdrawal (cyclosporine or tacrolimus)
Number of subjects: 0
Study 15919453 — intervention group
Group type: COMPARATOR
Intervention: CNI continuation (cyclosporine or tacrolimus)
Number of subjects: 0
Study 12949361 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low carbohydrate diet (<10% carbohydrate)
Number of subjects: 10
Study 12949361 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet (<30% fat)
Number of subjects: 10
Study 10930115 — intervention group
Group type: EXPERIMENTAL
Intervention: IBR/CT group
Number of subjects: 52
Study 10930115 — intervention group
Group type: COMPARATOR
Intervention: CT group
Number of subjects: 52
Study 8889437 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter diet
Number of subjects: 8
Study 8889437 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallow diet
Number of subjects: 8
Study 8889437 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil diet
Number of subjects: 8
Study 8889437 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 8
Study 1739722 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymacon intraocular lens
Number of subjects: 290
Study 1739722 — intervention group
Group type: COMPARATOR
Intervention: PMMA intraocular lens
Number of subjects: 290
Study 6415744 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg naloxone
Number of subjects: 6
Study 6415744 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study 30857514 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7000
Study 30857514 — intervention group
Group type: COMPARATOR
Intervention: Intermittent infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Number of subjects: 7000